Confidential Institutional Briefing

Engineering the Brain's
Repair Circuitry.

Xycota is a clinical-stage biotechnology platform engineering precision delivery systems to physically restore synaptic connectivity. We leverage a targeted, non-psychoactive psilocin paradigm to directly upregulate the BDNF-TrkB pathway, driving structural neuroplasticity.

Access Institutional Data Room

Authorized Strategic Partners & Investors Only

Clinical Development

Development Pipeline

Lead Asset: FTD / Neuroplastic Repair

Frontotemporal Dementia (Orphan Designation Target)

Pre-IND / Formulation Complete Phase 1/2a

Expansion Asset: mTBI

Post-Concussion Cognitive Restoration

Platform Expansion Target Exploratory R&D

Future Asset: ALS & Memory Care

Broad-Spectrum Synaptic Degeneration

Strategic Roadmap Future Licensing

Execution & Exit History

De-Risked Execution.
Proven Clinical Leadership.

We are not funding discovery; we are advancing a de-risked biological mechanism. Xycota is anchored by Dr. Marvin S. Hausman, MD. With a 50-year track record in CNS drug development, Dr. Hausman has architected 6 successful NDAs, pioneered foundational Orphan Drug designations in the U.S. and EU, and achieved a major strategic exit via Medco Research (acquired by Pfizer).

"Xycota was formed to build a standardized biological interface for repairing the human brain, backed by institutional capital discipline."

Dr. Marvin S. Hausman, MD | Founder & CSO

6

Successful FDA NDAs

50+

Years in CNS Drug Dev

Pfizer

Acquired Prior Venture

Mechanistic Validation

Decoupling Healing
from Hallucination.

For decades, capital markets assumed the therapeutic benefits of psilocybin were intrinsically tied to the 5-HT2A psychedelic experience. Recent pre-clinical data materially invalidates this paradigm.

Objective cognitive restoration persists despite 5-HT2A blockade, but disappears entirely when TrkB signaling is inhibited. The true restorative benefit is strictly driven by the BDNF/TrkB signaling pathway. Xycota isolates this mechanism, delivering precise upregulation without the hallucinogenic liability.

"We are not chasing the trip.
We are engineering the repair."

Mechanism of Action

Engineered Exosome Delivery

Active moiety formulation (Psilocin)

Blood-Brain Barrier Penetration

First-pass liver metabolism bypassed

BDNF/TrkB Upregulation

5-HT2A psychedelic receptors bypassed

Endogenous Synaptogenesis

Physical Hardware Repair Achieved

Strategic Entry

The Clinical Wedge: FTD

Frontotemporal Dementia (FTD) presents a highly capital-efficient pathway to achieve human proof-of-concept and unlock platform value.

Mechanistic Alignment

FTD is characterized by rapid synaptic decay, presenting a direct, verifiable target for our synaptogenic mechanism.

Zero Approved Restoratives

An extreme unmet clinical need exists with no FDA-approved therapies capable of reversing disease progression.

Regulatory Efficiency

Orphan Drug Designation (ODD) secures 7-year market exclusivity, fee waivers, and a streamlined trial architecture.

Platform Expansion

Achieving a human signal in FTD de-risks the underlying mechanism, instantly unlocking broader markets (mTBI, ALS).

The Investment Thesis

A De-Risked Platform

Data Anchored

Validated by robust, peer-reviewed BDNF–TrkB pre-clinical evidence.

Precision Delivery

Engineered exosome formulation protecting the active moiety.

Defensible IP Moat

Provisional patent protection securing active loading methodologies.

Capital Efficient

Strategic FTD focus enables smaller, faster clinical trials.

Institutional Infra.

Established clinical and manufacturing partnerships active.

Leadership

Scientific & Corporate Governance

Led by pioneers in immunology, corporate architecture, and drug development.

Brad Listermann

Brad Listermann

President & Co-Founder

Technology visionary and public company architect holding multiple patents. Proven track record of developing and licensing complex technology platforms to the U.S. Government (USG) and global private sectors. Expert in capital market strategy, regulatory compliance, and accelerating biotech commercialization.

Dr. Marvin Hausman

Dr. Marvin S. Hausman, MD

Founder and CSO

World-renowned immunologist and board-certified surgeon with over 50 years of experience in the biopharmaceutical industry. Co-founder of Medco Research (acquired by Pfizer), key developer of the blockbuster antidepressant Wellbutrin®, and architect of 6 successful NDAs.

Scientific Advisory Board

Dr. Viviana Trezza

Dr. Viviana Trezza, PhD

Advisor | Pharmacology

Dr. Louise Hecker

Dr. Louise Hecker, PhD

Advisor | Cellular Biology

Andrew Charrette

Andrew Charrette, MSc

Director | Regulatory Affairs

Scientific Foundations & News

Official Press Announcement

Nature Portfolio
Neuropsychopharmacology

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.

Published Findings
Trezza, V., Hausman, M. S., et al. (2026)

Nature Portfolio
npj Aging (Request Access)

Psilocin identifies as a direct modulator of cellular lifespan and telomere integrity in aged models.

Published Findings
Hecker, L., Hausman, M. S., et al. (2025)

Get in Touch

Partnering for the Future
of Brain Repair.

For institutional inquiries, strategic briefings, or data room access, please connect with our leadership team.

Contact Us